Doug Sommerville, senior vice-president and general manager of Teva Canada, discusses Teva Canada’s enviable top five positioning within the global organization, the strength of Teva’s generics portfolio within Canada, and the critical importance of Canada possessing a local pharma manufacturing industry.
Teva recently announced a new global CEO, Kåre Schultz. What do you foresee to be the impact of this appointment on Teva globally – and the Canadian affiliate?
"Teva has had some really successful challenges to brand companies’ patented medicines where we were able to bring products to market early, thus saving millions of taxpayer dollars."
